Pacer Advisors
STOK icon

Pacer Advisors’s Stoke Therapeutics STOK Stock Holding History

Pacer Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-454
Closed -$6.13K – 2689
2024
Q2 		$6.13K Buy
+454
New +$6.13K ﹤0.01% 3618
2021
Q2 		– Sell
-811
Closed -$31K – 1547
2021
Q1 		$31K Buy
811
+384
+90% +$21.9K ﹤0.01% 1477
2020
Q4 		$26K Buy
+427
New +$19.6K ﹤0.01% 1470

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors's STOK Position: Q3 2024 in Review

Pacer Advisors sold out of Stoke Therapeutics (STOK) in Q3 2024, closing a stake of 454 shares — an estimated $6.13K sold.

Pacer Advisors first reported a position in STOK in Q4 2020 and held it in 3 quarters. The position peaked at $31K in Q1 2021. 118 funds tracked by Wall St. Rank hold STOK as of Q3 2024.

  • Pacer Advisors reported no remaining Stoke Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 454 Stoke Therapeutics shares in Q3 2024, an estimated $6.13K.
  • Pacer Advisors first reported a position in Stoke Therapeutics in Q4 2020 and held it in 3 quarters.
  • Pacer Advisors's Stoke Therapeutics position peaked at $31K in Q1 2021.
  • 118 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.